Mo­men­ta hit with a set­back as pan­cre­at­ic can­cer drug flops in PhII

Mo­men­ta Phar­ma­ceu­ti­cals has been hit with a set­back. The Cam­bridge, MA-based biotech says that its Phase II study match­ing the ex­per­i­men­tal necu­paranib with Abrax­ane and gem­c­itabine failed to make an ap­pre­cia­ble dent in metasta­t­ic pan­cre­at­ic can­cer.

At the halfway point of the study, with 57 deaths, the da­ta mon­i­tor­ing com­mit­tee de­cid­ed that they weren’t see­ing any ev­i­dence that the drug was mak­ing a sig­nif­i­cant dif­fer­ence for pa­tients. Now they’re shut­ting the study down and un­blind­ing the da­ta to see what the next best step will be for the pa­tients who are left.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER